A Novel Peptide ADAM8 Inhibitor Attenuates Bronchial Hyperresponsiveness and Th2 Cytokine Mediated Inflammation of Murine Asthmatic Models.

Jun Chen,Linhong Deng,Daniela Dreymüller,Xuemei Jiang,Jiaoyue Long,Yiyuan Duan,Yue Wang,Mingzhi Luo,Feng Lin,Lizhen Mao,Bernd Müller,Garrit Koller,Jörg W. Bartsch
DOI: https://doi.org/10.1038/srep30451
IF: 4.6
2016-01-01
Scientific Reports
Abstract:A disintegrin and metalloproteinase 8 (ADAM8) has been identified as a signature gene associated with moderate and severe asthma. Studies in mice have demonstrated that the severity of asthma can be reduced by either transgenic knock-out or by antibodies blocking ADAM8 function, highlighting ADAM8 as potential drug target for asthma therapy. Here, we examined the therapeutic effect of an ADAM8 inhibitor peptide (BK-1361) that specifically blocks cellular ADAM8 activity in ovalbumin-sensitized and challenged Balb/c mice. We found that BK-1361 (25 μg/g body weight) attenuated airway responsiveness to methacholine stimulation by up to 42%, concomitantly reduced tissue remodeling by 50% and decreased inflammatory cells (e.g. eosinophils down by 54%)/inflammatory factors (e.g. sCD23 down by 50%)/T H 2 cytokines (e.g. IL-5 down by 70%)/ADAM8-positive eosinophils (down by 60%) in the lung. We further verified that BK-1361 specifically targets ADAM8 in vivo as the peptide caused significantly reduced levels of soluble CD23 in wild-type but not in ADAM8-deficient mice. These findings suggest that BK-1361 blocks ADAM8-dependent asthma effects in vivo by inhibiting infiltration of eosinophils and T H 2 lymphocytes, thus leading to reduction of T H 2-mediated inflammation, tissue remodeling and bronchial hyperresponsiveness. Taken together, pharmacological ADAM8 inhibition appears as promising novel therapeutic strategy for the treatment of asthma.
What problem does this paper attempt to address?